Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
UMC starts mass production of silicon photonics wafers in Singapore
07/14/2026 04:41 PM - Business
Taiex under heavy pressure but late rebound caps fall
07/14/2026 04:29 PM - Society
Costco-imported frozen vegetables fail Taiwan pesticide inspection
07/14/2026 04:24 PM - Business
U.S. dollar closes higher on Taipei forex market
07/14/2026 04:16 PM - Politics
Black Hawk helicopter airlifts fuel bladder in battlefield resupply exercise
07/14/2026 04:14 PM